Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily

References

• ANDERSSON T., MINERS, J. O., VERONESE M. E., TASSANEEYAKUL W., TASSANEEYAKUL W., MEYER, U. A. and BIRKETT, D. J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 521–530.
   PubMed Web of Science ®Google Scholar
• BAJPAI, M., Rosxos, L. K., SHEN, D. D. and LEVY, R. H., 1996, Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metabolism and Disposition, 24, 1401–1403.
   PubMed Web of Science ®Google Scholar
• BIRKETT, D. J., ANDERSSON, T. and MINERS, J. O., 1996, Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. Methods in Enzymology, 272, 132–139.
   PubMed Web of Science ®Google Scholar
• DEGTYARENKO, K. N. and ARCHAKOV, A. I., 1993, Molecular evolution of P450 superfamily and P450-containing monoxygenase systems. FEBS Letters, 332, 1–8.
   PubMed Web of Science ®Google Scholar
• FALETTO, M. B., LINKO, P. and GOLDSTEIN, J. A., 1992, A single amino acid mutation (Ser's° —> Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. Journal of Biological Chemistry, 267, 2032–2037.
   PubMedGoogle Scholar
• FUCK-BRETANO, C., BECQUEMONT, L., LENEVEU, A., Roux, A., JAILLoN, P. and BEAUNE, P., 1997, Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. Journal of Pharmacology and Experimental Therapeutics, 280, 730–738.
   PubMedGoogle Scholar
• FUNCK -BRENTANO, C., Bosco, O., JAcoz-AioRAIN, E., KEUNDJIAN, A. and JAILLoN, P., 1992, Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clinical Pharmacology and Therapeutics, 51, 507–512.
   PubMedGoogle Scholar
• GOLDSTEIN, J. A., FALETTO, M. B., ROMKES -SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry, 33, 1743–1752.
   Google Scholar
• GOLDSTEIN, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285–299.
   PubMedGoogle Scholar
• GOTOH, O., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83–90.
   PubMed Web of Science ®Google Scholar
• GRAHAM -LORENCE, S. and PETERSON, J. A., 1996, P450s : structural similarities and functional differences. FASEB Journal, 10, 206–214.
   PubMedGoogle Scholar
• GRAM, L. F., GUENTERT, T. W., GRANGE, S., VISTISEN, K. and BROSEN, K., 1995, Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clinical Pharmacology of Therapeutics, 57, 670–677.
   PubMed Web of Science ®Google Scholar
• HALL, S. D., GUENGERICH, F. P., BRANCH, R. A. and WILKINSON, G. R., 1987, Characterization and inhibition of mephenytoin 4 -hydroxylase activity in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 240, 216–222.
   PubMed Web of Science ®Google Scholar
• HANSCH, C., B.loRKROTH, J. P. and LEO, A., 1987, Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. Journal of Pharmaceutical Sciences, 76, 663–687.
   Google Scholar
• HANSCH, C. and LEO, A., 1979, Substituent Constants for Correlation Analysis in Chemistry and Biology (New York: Wiley).
   Google Scholar
• HASEMANN, C. A., KURUMBAIL, R. G., BODDUPALLI, S. S., PETERSON, J. A. and DEISENHOFER, J., 1995, Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure, 3, 41–62.
   PubMed Web of Science ®Google Scholar
• HSU, M.-H., GRIFFIN, K. J., WANG, Y., KEMPER, B. and JOHNSON, E. F., 1993, A single amino acid substitution confers progesterone 6/3-hydroxylase activity to rabbit cytochrome P450 2C3. Journal of Biological Chemistry, 268, 6939–6944.
   PubMed Web of Science ®Google Scholar
• IBEANU, G. C., GHANAYEM, B. I., LINKO, P., LI, L., PEDERSEN, L. G. and GOLDSTEIN, J. A., 1996, Identification of residues 99,220 and 221 of human cytochrome P4502C19 as key determinants of omeprazole hydroxylase activity. Journal of Biological Chemistry, 271, 12496–12501.
   PubMed Web of Science ®Google Scholar
• IMM, Y. and NAKAMURA, M., 1989, Point mutations at threonine-301 modify substrate specificity of rabbit liver microsomal cytochromes P-450 (laurate (co-1)-hydroxylase and testosterone 16a-hydroxylase). Biochemical and Biophysical Research Communications, 158, 717–722.
   PubMedGoogle Scholar
• INOUE, K., YAMAZAKI, H., ImIYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and s-mephenytoin 4'-hydroxylation activities in livers of japanese and caucasian populations. Pharmacogenetks, 7, 103–113.
   PubMedGoogle Scholar
• JOHNSON, E. F., 1992, Mapping determinants of the substrate selectivity of P450 enzymes by site-directed mutagenesis. Trends in Pharmaceutical Sciences, 13, 122–126.
   PubMed Web of Science ®Google Scholar
• JOS, B. C., HAWKSWORTH, G., HORNE, V. A., NEWLANDS, A., MORSMAN, J., TUTE, M. S. and SMITH, D. A., 1996b, Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metabolism and Disposition, 24, 260–266.
   PubMedGoogle Scholar
• JOS, B. C., HAWKSWORTH, G., HORNE, V., NEWLANDS, A., TUTE, M. and SMITH, D. A., 1993, Putative active site model for CYP2C9 (tolbutamide hydro xylase). British Journal of Clinical Pharmacology, 36, 143P–144P.
   Google Scholar
• JONES, J. P., HE, M., TRAGER, W. F. and RETTlE, A. E., 1996a, Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metabolism and Disposition, 24, 1–6.
   PubMed Web of Science ®Google Scholar
• KAMINSKY, L. S., DE MORAIS, S. M. F., FALETTO, M. B., DUNBAR, D. A. and GOLDSTEIN, J. A., 1993, Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Molecular Pharmacology, 43, 234–239.
   Google Scholar
• KARAM, W. G., GOLDSTEIN, J. A., LASICER, J. M. and GHANAYEM, B. I., 1996, Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition, 24, 1081–1087.
   PubMed Web of Science ®Google Scholar
• KORZEKWA, K. R. and JoNEs, J. P., 1993, Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1–18.
   PubMedGoogle Scholar
• KRONBACH, T. and JOHNSON, E. F., 1991, An inhibitory monoclonal antibody binds in close proximity to a determinant for substrate binding in cytochrome P450I105. Journal of Biological Chemistry, 266, 6215–6220.
   PubMed Web of Science ®Google Scholar
• KRONBACH, T., KEMPER, B. and JOHNSON, E. F., 1991, A hypervariable region of P450I105 confers progesterone 21-hydroxylase activity to P450I1C1. Biochemistry, 30, 6097–6102.
   PubMed Web of Science ®Google Scholar
• KRONBACH, T., LARABEE, T. M. and JOHNSON, E. F., 1989, Hybrid cytochromes, P-450 identify a substrate binding domain in P-450I105 and P-450I1C4. Proceedings of the National Academy of Sciences, USA, 86, 8262–8265.
   PubMed Web of Science ®Google Scholar
• KUPFER, A. and BRANCH, R. A., 1985, Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clinical Pharmacology and Therapeutics, 38, 414–418.
   PubMed Web of Science ®Google Scholar
• LAKE, B. G. and LEWIS, D. F. V., 1996, The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects edited by C. Ioannides (Boca Raton: CRC Press, chapter 11.
   Google Scholar
• LEVITT, M. and PERUTZ, M. F., 1988, Aromatic rings act as hydrogen bond acceptors. Journal of Molecular Biology, 201, 751–754.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., 1995, Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450b„3). Xenobiotka, 25, 333–366.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., 1996a, Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis).
   Google Scholar
• LEWIS, D. F. V., 1996b, Molecular modelling of mammalian cytochromes P450 with specific substrates and inhibitors. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (Boca Raton, CRC Press), chapter 14.
   Google Scholar
• LEWIS, D. F. V. and LAKE, B. G., 1995, Molecular modelling of members of the CYP2A subfamily: application to studies of enzyme specificity, Xenobiotka, 25, 585–598.
   Google Scholar
• LEWIS, D. F. V. and LAKE, B. G., 1996, Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site residues, Xenobiotica, 26, 723–753.
   Google Scholar
• LOPEZ-GARCIA, M. P., DANSETTE, P. M., VALADON, P., AMAR, C., BEAUNE, P. H., GuENGERIcH, F. P. and MANSUY, D., 1993, Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies: oxidative activation of tienilic acid by cytochromes P-4502C9 and 2C10, European Journal of Biochemistry, 213, 223–232.
   Google Scholar
• MANCY, A., BROTO, P., DIJOLS, S., DANSETTE, P. M. and MANSUY, D., 1995, The substrate binding site of human liver cytochrome P4502C9: an approach using designed tienilic acid derivatives and molecular modelling, Biochemistry, 34, 10365–10375.
   Google Scholar
• MANCY, A., DuoLs, S., Poi, S., GUENGERICH, F. P. and MANSUY, D., 1996, Interaction of sulfaphenazole derivatives with human liver cytochromes P4502C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9, Biochemistry, 35, 16205–16212.
   Google Scholar
• MINERS, J. O. and BIRKETT, D. J., 1996, Use of tolbutamide as a substrate probe for human hepatic cytochrome P4502C9, Methods in Enzymology, 272, 139–145.
   Google Scholar
• MORSMAN, J. M., SMITH, D. A., Jos, B. C. and HAWKSWORTH, G. M., 1995, Role of hydrogen-bonding in substrate structure-activity relationships for CYP2C9. In Proceedings of the 4th International ISSX Meeting, Seattle, Washington, USA, 27–31 August, p. 259.
   Google Scholar
• NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, GONZALEZ, F. J., COON, M. J., GUNSALUS I. C., GOTOH, O., OKUDA, K. and NEBERT, D. W., 1993, The P-450 superfamily : update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature, DNA and Cell Biology, 12, 1–51.
   Google Scholar
• NELSON D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., GUNSALUS I. C. and NEBERT, D. W., 1996, CYP450 superfamily : update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetks, 6, 1–42.
   Google Scholar
• OHGIYA, S., KOMORI, M., OHI, H., SHIRAMATSU, K., SHINRIKI, N. and KAMATAKI, T., 1992, Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity, Biochemistry International, 27, 1073–1081.
   Google Scholar
• RAVICHANDRAN, K. G., BODDUPALLI, S. S., HASEMANN, C. A., PETERSON, J. A. and DEISENHOFER, J., 1993, Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450s, Science, 261, 731–736.
   Google Scholar
• REKKER, R. F., TER LAAK, A. M. and MANNHOLD, R., 1993, On the reliability of calculated log P values: Rekker, Hansch/Leo and Suzuki approach, Quantitative Structure-Activity Relationships, 12, 152–157.
   Google Scholar
• RETTlE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. D., AOYAMA, T., GELBOIN H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions, Chemical Research in Toxicology, 5, 54–59.
   Google Scholar
• RICHARDSON, T. H. and JOHNSON, E. F., 1994, Alterations of the regiospecificity of progesterone metabolism by the mutagenesis of two ken amino acid residues in rabbit cytochrome P450 2C3v, Journal of Biological Chemistry, 269, 23937–23943.
   Google Scholar
• SANGSTER, J., 1989, Octanol-water partition coefficients of simple organic compounds, Journal of Physical and Chemical Reference Data, 18, 1111–1229.
   Google Scholar
• SMINI, D. A. and Jos, B. C., 1992, Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes, Biochemical Pharmacology, 44, 2089–2098.
   Google Scholar
• STRAUB, P., JOHNSON, E. F. and KEMPER, B., 1993b, Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity, Archives of Biochemistry and Biophysics, 306, 521–527.
   Google Scholar
• STRAUB, P., LLOYD, M., JOHNSON, E. F. and KEMPER, B., 1993a, Cassette mutagenesis of a potential substrate recognition region of cytochrome P450 2C2, Journal of Biological Chemistry, 268, 21997–22003.
   Google Scholar
• Suzum, T. and KUDO, Y., 1990, Automatic log P estimation based on combined additive modeling methods, Journal of Computer-Aided Molecular Design, 4, 155–198.
   Google Scholar
• VERONESE M. E., DOECKE, C. J., MACKENZIE, P.1., McMANus, M. E., MINERS, J. O., REES, D. L. P., GASSER, R., MEYER, V. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily, Biochemical Journal, 289, 533–538.
   Google Scholar
• WACHENFELDT, C. V. and JOHNSON, E. F., 1995, Structures of eukaryotic cytochrome P450 enzymes. In Cytochrome P450, edited by P. R. Ortiz de Montellano (New York: Plenum), pp. 183–223.
   Google Scholar
• WEAVER, R. J., DICKINS, M., WALLER, S. J., CHAMBERS, J. M., MORLEY, T. J. and BURKE, M. D., 1995, Proguanil metabolism in hepatic microsomes and isolated hepatocytes from animals and man, and the effect of Atovaquone and CYP inhibitors. In Proceedings of the 4th International IS SX Meeting, Seattle, Washington, USA, 27–31 August, p. 295.
   Google Scholar
• WEDLAND, P. J. and WILKINSON, G. R., 1996, In vivo and in vitro measurement of CYP2C19 activity, Methods in Enzymology, 272, 105–114.
   Google Scholar
• WHITE, I. N. H., DE MATTEIS, F., GIBBS, A. H., Lim, C. K., WOLF, C. R., HENDERSON, C. and SMITH, L. L., 1995, Species differences in the covalent binding of ['4C] tamoxifen to liver microsomes and the forms of cytochrome P450 involved, Biochemical Pharmacology, 49, 1035–1042.
   Google Scholar
• W1ENKERS, L. C., WURDEN, C. J., STORCH, E., KUNZE, K. L., RETTIE, A. E. and TRAGER, W. F., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes, Drug Metabolism and Dis-position, 24, 610–614.
   Google Scholar
• WISEMAN, H. and LEWIS, D. F. V., 1996, The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anticarcinogenic/carcinogenic actions, Carcinogen esis, 17, 1357–1360.
   Google Scholar
• WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VAN DEN BRANDEN, M., 1993, Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S - mephenytoin 4'-hydroxylation, Archives of Biochemistry and Biophysics, 306, 240–245.
   Google Scholar
• YAMAZAKI, S., SATO, K., SUHARA, K., SAKAGUCHI, M., MIHARA, K. and OMURA, T., 1993, Importance Of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s, Journal of Biochemistry (Tokyo), 114, 652–657.
   Google Scholar